Jul 05, 2022 6:00am EDT Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
Jun 23, 2022 4:00pm EDT Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
May 24, 2022 4:00pm EDT Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
May 11, 2022 9:00am EDT Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates
Apr 01, 2022 7:00am EDT Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission
Feb 11, 2022 8:00am EST Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates
Jan 06, 2022 7:00am EST Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
Jan 06, 2022 7:00am EST Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations
Jan 04, 2022 7:00am EST Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director
Jan 03, 2022 7:00am EST Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication
